# US 10,479,832 B2 · Method of treating bone disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,479,832 B2
- Document ID: US10479832B2
- Status: Granted
- Kind: B2
- Application number: 15/129,792
- Filed: 2015-03-30
- Published: 2017-05-11
- Granted: 2019-11-19
- Earliest claimed: 2014-03-31
- Assignees: Universiteit Gent; Vib Vzw
- Applicants: Universiteit Gent; Vib Vzw
- Inventors: Dirk Elewaut; Els Louagie; Nele Juchtmans
- Web page: https://patentgrep.com/patent/US10479832B2

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A01K 67/0276: Knock-out vertebrates
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2267/0368: Animal model for inflammation
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The disclosure provides compositions and methods comprising a sialoadhesin binding moiety for treating metabolic and genetic bone disease, especially for treating a bone disorder of hyper-resorption of bone and/or enhanced activation of osteoclasts.

## Claims

### Claim 1

A pharmaceutical composition comprising:
an antibody that specifically binds sialoadhesin (Sn);
an agent for treating bone disorders in an amount useful for the treatment of a bone loss disorder or bone loss disorders in the subject; and
a pharmaceutically acceptable carrier and/or excipient.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antibody antagonizes sialoadhesin-mediated osteoclast fusion.

### Claim 3 (depends on 1)

The pharmaceutical of claim 1, wherein the agent for treating bone disorders is selected from the group consisting of estrogens, selective estrogen receptor modulators, alendronate, risedronate, calcitonin, parathyroid hormone, Teriparatide, RANKL inhibitors, cathepsin K inhibitors, integrin inhibitors, src inhibitors, V-ATPase inhibitors, bafilomycin; zoledronic acid, clodronate, tiludronate, pamidronate, etidronate, ibandronate, partial estrogen agonists and antagonists, genistein, daidzein and related phytoestrogens, tamoxifen, bone binding transition metals gallium, thallium, and indium, and inhibitors of chloride channel activity.

### Claim 4

A pharmaceutical composition comprising:
an antibody that specifically binds sialoadhesin (Sn);
an agent for treating bone disorders; and
a pharmaceutically acceptable carrier and/or excipient.

### Claim 5 (depends on 4)

The pharmaceutical of claim 4, wherein the agent for treating bone disorders is selected from the group consisting of estrogens, selective estrogen receptor modulators, alendronate, risedronate, calcitonin, parathyroid hormone, Teriparatide, RANKL inhibitors, cathepsin K inhibitors, integrin inhibitors, src inhibitors, V-ATPase inhibitors, bafilomycin; zoledronic acid, clodronate, tiludronate, pamidronate, etidronate, ibandronate, partial estrogen agonists and antagonists, genistein, daidzein and related phytoestrogens, tamoxifen, bone binding transition metals gallium, thallium, and indium, and inhibitors of chloride channel activity.